Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abeona Therapeutics Inc. - Common Stock (NQ:ABEO)

5.070 -0.280 (-5.23%)
Streaming Delayed Price Updated: 9:59 AM EDT, Apr 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,113,220
Open 5.320
Bid (Size) 5.060 (13)
Ask (Size) 5.080 (3)
Prev. Close 5.350
Today's Range 4.970 - 5.365
52wk Range 3.370 - 6.780
Shares Outstanding 48,533,798
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
-14.2%
-14.2%
1 Month
+6.5%
+6.5%
3 Month
-4.3%
-4.3%
6 Month
-20.7%
-20.7%
1 Year
+47.4%
+47.4%

More News

Read More
Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans
From Abeona Therapeutics Inc.
Via GlobeNewswire
This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces Participation in November Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel
From Abeona Therapeutics Inc.
Via GlobeNewswire
ABEO Stock Earnings: Abeona Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Abeona Therapeutics Inc. - Common Stock publicly traded?
Yes, Abeona Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Abeona Therapeutics Inc. - Common Stock trade on?
Abeona Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Abeona Therapeutics Inc. - Common Stock?
The ticker symbol for Abeona Therapeutics Inc. - Common Stock is ABEO on the Nasdaq Stock Market
What is the current price of Abeona Therapeutics Inc. - Common Stock?
The current price of Abeona Therapeutics Inc. - Common Stock is 5.070
When was Abeona Therapeutics Inc. - Common Stock last traded?
The last trade of Abeona Therapeutics Inc. - Common Stock was at 04/29/25 09:59 AM ET
What is the market capitalization of Abeona Therapeutics Inc. - Common Stock?
The market capitalization of Abeona Therapeutics Inc. - Common Stock is 246.07M
How many shares of Abeona Therapeutics Inc. - Common Stock are outstanding?
Abeona Therapeutics Inc. - Common Stock has 246M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.